Detalhe da pesquisa
1.
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.
Invest New Drugs
; 41(1): 115-121, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36633784
2.
The Glasgow Prognostic Score Predicts Survival Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer.
Oncology
; 101(11): 695-704, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37494886
3.
The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer.
Oncology
; 101(1): 69-76, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36103811
4.
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
Oncology
; 101(11): 685-694, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37166346
5.
Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease.
Invest New Drugs
; 40(1): 182-189, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34415485
6.
First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.
Invest New Drugs
; 40(2): 430-437, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34807331
7.
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
BMC Cancer
; 22(1): 1314, 2022 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36522630
8.
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320).
Invest New Drugs
; 39(2): 530-536, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33159674
9.
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.
Invest New Drugs
; 38(6): 1906-1914, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32415486
10.
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
Invest New Drugs
; 38(3): 885-893, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32157598
11.
Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer.
Am J Pathol
; 188(6): 1328-1333, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29751934
12.
Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
BMC Cancer
; 19(1): 163, 2019 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30808322
13.
Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer.
Invest New Drugs
; 36(1): 45-52, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28466376
14.
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Oncology
; 94(4): 207-214, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29393275
15.
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Oncology
; 95(2): 109-115, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29698957
16.
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
BMC Cancer
; 18(1): 241, 2018 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29499653
17.
The role of prophylactic cranial irradiation for patients with small-cell lung cancer.
Jpn J Clin Oncol
; 48(1): 26-30, 2018 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29077861
18.
Basigin expression as a prognostic indicator in stage I pulmonary adenocarcinoma.
Pathol Int
; 68(4): 232-240, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29431238
19.
Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
Invest New Drugs
; 35(5): 642-648, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28631097
20.
Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Oncology
; 92(5): 283-290, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28222447